Rapid progression of prostate cancer in men with a BRCA2 mutation |
| |
| Authors: | Narod S A,Neuhausen S,Vichodez G,Armel S,Lynch H T,Ghadirian P,Cummings S,Olopade O,Stoppa-Lyonnet D,Couch F,Wagner T,Warner E,Foulkes W D,Saal H,Weitzel J,Tulman A,Poll A,Nam R,Sun P Hereditary Breast Cancer Study Group,Danquah Jessica,Domchek Susan,Tung Nadine,Ainsworth Peter,Horsman Douglas,Kim-Sing Charmaine,Maugard Christine,Eisen Andrea,Daly Mary,McKinnon Wendy,Wood Marie,Isaacs Claudine,Gilchrist Dawna,Karlan Beth,Nedelcu Raluca,Meschino Wendy,Garber Judy,Pasini Barbara,Manoukian Siranoush,Bellati Christina |
| |
| Affiliation: | Women's College Research Institute, 790 Bay Street, 7th Floor, Women's College Hospital, University of Toronto, Toronto, Ontario, Canada. steven.narod@wchospital.ca |
| |
| Abstract: | ![]()
Men with BRCA2 mutations have been found to be at increased risk of developing prostate cancer. There is a recent report that BRCA2 carriers with prostate cancer have poorer survival than noncarrier prostate cancer patients. In this study, we compared survival of men with a BRCA2 mutation and prostate cancer with that of men with a BRCA1 mutation and prostate cancer. We obtained the age at diagnosis, age at death or current age from 182 men with prostate cancer from families with a BRCA2 mutation and from 119 men with prostate cancer from families with a BRCA1 mutation. The median survival from diagnosis was 4.0 years for men with a BRCA2 mutation vs 8.0 years for men with a BRCA1 mutation, and the difference was highly significant (P<0.01). It may be important to develop targeted chemotherapies to treat prostate cancer in men with a BRCA2 mutation. |
| |
| Keywords: | prostate cancer BRCA1 BRCA2 |
| 本文献已被 PubMed 等数据库收录！ |
|
